Matthew specialises in patent litigation, opinion work, supplementary protection certificates (SPCs), paediatric extensions and regulatory advice.
Matthew has a strong science background, holding a PhD in molecular immunology, meaning he gets to grips with the scientific facts of a case quickly.
A leading individual in Chambers and is a rising star in litigation, Matthew has particular experience of acting for clients in the pharmaeutical, biotech and life sciences sectors. He regularly co-ordinates pan-European litigation and has been involved in hearings in Germany, Netherlands, Belgium and Norway.
EU Guidance on biosimilar MAbs - what took so long?, Scrip Regulatory Affairs, pp 10-12, 17, July 2012
Neurim - EU Advocate General argues that supplementary protection certificates should be allowed for usage patents, Scrip Regulatory Affairs, p 5, 22, May 2012
Patent star
Life Sciences (IP/patent litigation) - Band 2: Matthew Royle frequently represents pharmaceutical manufacturers in contentious work regarding patent infringement claims, revocation actions and secondary use SPCs. Prior to his legal career he undertook a doctorate in medical microbiology. "A well-respected litigator." "Matthew Royle is clearly very clever and good at managing challenging situations."
Intellectual Property (patent litigation) - Band 3: Matthew Royle acts for pharmaceutical companies in patent litigation and also advises them on SPCs and regulation. He has taken a number of cases to the UK Supreme Court.
Life Sciences - IP/Patent Litigation: "A good litigator, with a good knowledge of the life sciences sector. He has a particular focus on the generics side."
Intellectual Property - Patent Litigation
"The Impact Case of the Year" for Actavis v ICOS case, where we acted for Mylan in relation to litigation on two patents relating to Lilly's blockbuster drug Cialis® (tadalafil).
Leading individual - Life Sciences: IP/Patent (band 3) and IP: patent litigation (band 4).
Leading individual - Life Sciences: IP/Patent litigation (Band 3): Matthew Royle frequently represents pharmaceutical manufacturers in contentious work regarding patent infringement claims, revocation actions and secondary use SPCs. A source says: "He is a very good patent litigator – sensible, pragmatic and a pleasure to work with."
Leading individual - Intellectual Property: Patent litigation (Band 4): Matthew Royle acts for pharmaceuticals companies in patent litigation and also advises them on SPCs and regulation. A source says: "He is a very good patent litigator - sensible, pragmatic and a pleasure to work with."
Leading individual - TMT: Pharmaceuticals and Biotech
Leading individual: litigation (Bronze): Matthew Royle is a canny and highly trained harvester of SPC extensions – a “well-known, longstanding presence in intellectual property”.
Leading individual: Patents
Patent star
For Pregabalin Supreme Court case
Leading individual - Intellectual Property: Patent Litigation (Band 4): Matthew Royle is a patent litigator and pharmaceuticals regulation expert with an academic background in medical microbiology. A source says: "He is a real hands-on partner in a lot of major cases."
Leading individual - Life Sciences: IP/Patent Litigation (Band 3): Matthew Royle is known for representing generic pharmaceutical manufacturers in high-stakes patent litigation such as patent revocation actions and disputes concerning contested SPCs. A source says: "He is a real hands-on partner in a lot of major cases."
Leading individual - Intellectual Property: Patent Litigation (Band 4): Matthew Royle is a rising life sciences patent litigator whose recent work has involved questions of secondary medical uses, dosage regimes and SPCs. A market commentator says he is "very strong on the science."
Leading individual - Life Sciences: IP/Patent Litigation (Band 3): Matthew Royle is distinguished for his representation of generic pharmaceutical manufacturers in high-value patent revocation actions and cases concerning SPCs. Sources note that he is "very strong on the science."
‘Rising star’ in litigation
A life sciences company on market formation dates in relation to orphan medicinal products.
A life sciences company on the validity of and expiry of supplementary protection certificates for a product launch.
A life sciences company on an EPO opposition in relation to a pharmaceutical.
A company dealing with commercialisation arrangements for university discoveries on a dispute between co-inventors in relation to a patent.
A life sciences company on data exclusivity in relation to a combination product in the context of a sale of that product.
作者
作者 Emma Danks 以及 Suzy Davis